The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.
possess a Greek social security number and are visiting hospitals/clinics, and/or other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,
are willing and able to provide written informed consent to participate in the study according to the study protocol.
Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).
bone marrow transplant
stem cell transplant
blood transfusion less than two weeks prior to buccal swab sample collection
The study will recruit and enroll eligible subjects possessing a Greek social security number, who are visiting hospitals/clinics and/or other private laboratory practices (incl. clinics and health care groups) as part of standard clinical practice.
Other
Prospective
Not listed
Allele frequency of HLA-alleles at the Greek population level
To assess the HLA allelic diversity of Greek population
Prevalence of selected HLA-related diseases in the Greek population
Characterization of the allelic and haplotypic HLA frequency distribution in the Greek population and comparison with global HLA databases.
Relative Risk (Risk Ratio (RR) or Odds Ratio (OR)) of HLA markers on diseases of interest
Evaluation of the association between HLA alleles and/or haplotypes, and selected diseases
Click on the lead sponsor to view all of their trials.
Athens LifeTech Park
Lead sponsor
Galatea.Bio
Collaborator
